Amy Proal

PolyBio’s Dr. Amy Proal

Medford, MA – July 24, 2025 –PolyBio Research Foundation announced today that Co-Founder and CEO Amy Proal, Ph.D., has joined the SPEAR (Spike Protein Elimination and Recovery) Study Group, a best-in-class clinical and translational research team convened by Invivyd, Inc. (Nasdaq: IVVD) to advance Long COVID clinic trials.

The SPEAR Study Group will structure and guide anticipated clinical trials evaluating the effects of broadly neutralizing anti-SARS-CoV-2 spike protein monoclonal antibody (mAb) therapy in people suffering from Long COVID or Post-Vaccination Syndrome (PVS), conditions believed to be mediated by persistent viral reservoirs or circulating spike protein. Persistent SARS-CoV-2 spike protein has been identified in both populations, and both populations have overlapping manifestations of apparent clinical disease. As many as 5% or more of Americans have reported recent Long COVID symptoms, an extraordinary medical burden that will continue to evolve as infections continue in the U.S.

The SPEAR Study Group was initiated in response to a growing number of case reports and reported case series from across the U.S. suggesting meaningful symptom relief / remission of Long COVID following use of PEMGARDA® (pemivibart), a monoclonal antibody currently authorized by the U.S. Food and Drug Administration (FDA) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain immunocompromised individuals. PEMGARDA is not authorized for the treatment of Long COVID. While these emerging reports are anecdotal and uncontrolled, they collectively support a longstanding, mechanistically plausible hypothesis: that prolonged exposure to pathogenic SARS-CoV-2 spike protein or other forms of persistent virus or viral material may drive disease in some patients, and that reducing this burden through monoclonal antibody therapy may offer a promising therapeutic approach worthy of rigorous clinical investigation. Clinical research to be planned by the SPEAR Study Group is critical to exploring disease biology and evaluating efficacy endpoints that can enable registrational studies if appropriate in the future.

The SPEAR Study Group unites leading scientists from PolyBio’s Long COVID Research Consortium (LCRC) in a groundbreaking industry–academic collaboration aimed at accelerating treatments for patients. Along with Invivyd, these researchers will collaborate on the design and anticipated execution of relevant clinical trials:

  • Amy Proal, Ph.D., Co-Founder and CEO, PolyBio Research Foundation and Scientific Director, Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases (“CoRE”)
  • Michael Peluso, M.D., MHS, Assistant Professor of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco
  • David Putrino, Ph.D., Nash Family Director of the Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases (“CoRE”) and Professor, Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai.
  • Akiko Iwasaki, Ph.D., Professor of Immunobiology, Yale School of Medicine and leader of groundbreaking Long COVID research initiatives such as the Yale LISTEN and Mount Sinai–Yale Long COVID studies.

The SPEAR Study Group intends to launch collaborative, multi-center translational clinical research on Long COVID, including PVS, as soon as practicable, including use of next-generation monoclonal antibody candidates from Invivyd such as VYD2311.

A patient receives a monoclonal antibody infusion.

PolyBio Research Foundation, which has catalyzed over$42 million in infection-associated chronic disease research since 2021, views this collaboration as a critical step towards bridging scientific discoveries about the root biological drivers of disease and patient-accessible treatments.

Said Dr. Proal, “We are at a pivotal moment in Long COVID research. By uniting experts in immunology, virology, rehabilitation, and translational medicine, the SPEAR Study Group is positioned to design the clinical studies that patients urgently need.”

“Long COVID is a pervasive, debilitating, and underappreciated public health challenge affecting millions of adults and children in the U.S., with no approved treatments,” added Marc Elia, Chairman of the Board at Invivyd. “Monoclonal antibodies have already demonstrated efficacy in preventing acute COVID-19 infections and treating acute COVID-19 infections, including long-term infections, and emerging anecdotal reports suggest pemivibart may have potential in addressing symptoms in some Long COVID patients. We believe that monoclonal antibodies are key to managing the ongoing burden of endemic COVID-19 disease in all forms, and as previously disclosed, we will be meeting with the FDA early in 3Q to discuss rapid approval pathways for COVID-19 mAbs. Meanwhile, our formation of the SPEAR Study Group is a critical step toward potentially unlocking a Long COVID treatment opportunity for patients in need by generating data needed to inform future studies and potential regulatory pathways. We look forward to sharing future milestones as we advance this important initiative.”

About PolyBio

PolyBio Research Foundation is a 501(c)3 transforming how complex chronic conditions like long COVID are studied, diagnosed, and treated. PolyBio conceptualizes research projects that identify root cause drivers of chronic conditions and builds collaborative teams to make the projects a reality.